IMMP vs. FHTX, ACRV, GTHX, GBIO, OVID, QURE, MACK, PRLD, CDT, and ALDX
Should you be buying Immutep stock or one of its competitors? The main competitors of Immutep include Foghorn Therapeutics (FHTX), Acrivon Therapeutics (ACRV), G1 Therapeutics (GTHX), Generation Bio (GBIO), Ovid Therapeutics (OVID), uniQure (QURE), Merrimack Pharmaceuticals (MACK), Prelude Therapeutics (PRLD), Conduit Pharmaceuticals (CDT), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical preparations" industry.
Immutep (NASDAQ:IMMP) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.
Immutep has higher earnings, but lower revenue than Foghorn Therapeutics.
2.3% of Immutep shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 3.1% of Immutep shares are held by company insiders. Comparatively, 9.2% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Immutep received 279 more outperform votes than Foghorn Therapeutics when rated by MarketBeat users. Likewise, 72.37% of users gave Immutep an outperform vote while only 57.69% of users gave Foghorn Therapeutics an outperform vote.
Immutep has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -288.17%.
Immutep currently has a consensus target price of $8.50, suggesting a potential upside of 230.74%. Foghorn Therapeutics has a consensus target price of $14.50, suggesting a potential upside of 187.13%. Given Immutep's stronger consensus rating and higher possible upside, analysts clearly believe Immutep is more favorable than Foghorn Therapeutics.
Immutep has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.13, indicating that its stock price is 213% more volatile than the S&P 500.
In the previous week, Immutep had 5 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 5 mentions for Immutep and 0 mentions for Foghorn Therapeutics. Immutep's average media sentiment score of 0.28 beat Foghorn Therapeutics' score of 0.00 indicating that Immutep is being referred to more favorably in the media.
Summary
Immutep beats Foghorn Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Immutep News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
